secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABVC BIOPHARMA, INC. (ABVC)
CIK:        0001173313
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001213900-24-041053
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ABVC licenses BLEX 404 to OncoX for pancreatic cancer; up to $13.75M in fees plus royalties
--------------------------------------------------------------------------------

- ABVC grants OncoX exclusive rights to develop/commercialize BLEX 404 for pancreatic cancer in 50% of worldwide markets for 20 years.
- OncoX to pay $6.25M (or 1.25M shares at $5) within 30 days; additional $0.625M milestone after next fundraising (no guarantee).
- ABVC entitled to 5% royalties on net sales, up to $12.5M; also may receive cash payments of at least $100K toward licensing fees.
- Press release states aggregate expected income of $13.75M and royalties up to $12.5M, but commercialization remains uncertain.
- Four FDA INDs approved for ABVC's oncology pipeline; ABV-1703 (BLEX 404) for pancreatic cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1173313/000121390024041053/0001213900-24-041053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1173313/000121390024041053/ea0205569-8k_abvcbio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-041053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer